The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Lynn Hunt, from Oxfordshire, England, told Newsweek: "I'm not a worrier, so the thought that the ulcer could be something sinister never crossed my mind." ...

Additionally, as a key powered secondary endpoint, the objective response rate (ORR) in the subcutaneous Opdivo arm (n=248 ... colorectal cancer, as a single agent or in combination with Yervoy; ...

The following week, I was diagnosed with squamous cell carcinoma (SCC ... The surgeons took a chunk of flesh and a vein from my arm to reconstruct a tongue flap. They also performed a skin ...

The two-arm registrational ... colorectal cancer. This is a significant development for the company as several highly prevalent solid tumors are MUC1 1 positive including non-small cell lung ...

Squamous cell carcinoma (SCC) is the main histological subtype in China ... feasibility for the regimen of sintilimab plus chemotherapy in ESCC. This open, single-arm pilot study was performed to ...